WallStreetZenWallStreetZen

NASDAQ: ABUS
Arbutus Biopharma Corp Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

ABUS past revenue growth

How has ABUS's revenue growth performed historically?
Company
-53.51%
Industry
148.64%
Market
17.33%
ABUS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ABUS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ABUS's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ABUS earnings and revenue history

Current Revenue
$18.1M
Current Earnings
-$72.8M
Current Profit Margin
-401.6%

ABUS Return on Equity

Current Company
-57.8%
Current Industry
-63.5%
Current Market
188%
ABUS's Return on Equity (-57.8%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when ABUS announces earnings.

ABUS Return on Assets

Current Company
-43.4%
Current Industry
2.9%
ABUS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ABUS Return on Capital Employed

Current Company
-59.38%
Current Industry
19.5%
ABUS's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ABUS vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ABUS$18.14M-$70.99M-$72.85M+25.00%N/A
URGN$82.71M-$81.90M-$102.24M+136.08%N/A
AVBP$0.00-$69.33M-$69.33MN/AN/A
ALEC$97.06M-$116.33M-$130.39M+28.52%N/A
ANAB$17.16M-$161.25M-$163.62M+27.97%N/A
View Top Biotech Stocks

ABUS earnings dates

Next earnings date
May 2, 2024

Arbutus Biopharma Earnings & Revenue FAQ

What were ABUS's earnings last quarter?

On Invalid Date, Arbutus Biopharma (NASDAQ: ABUS) reported Q4 2023 earnings per share (EPS) of -$0.12, up 14.29% year over year. Total Arbutus Biopharma earnings for the quarter were -$19.31 million. In the same quarter last year, Arbutus Biopharma's earnings per share (EPS) was -$0.14.

If you're new to stock investing, here's how to buy Arbutus Biopharma stock.

What was ABUS's earnings growth in the past year?

As of Q2 2024, Arbutus Biopharma's earnings has grown year over year. Arbutus Biopharma's earnings in the past year totalled -$72.85 million.

What is ABUS's earnings date?

Arbutus Biopharma's earnings date is Invalid Date. Add ABUS to your watchlist to be reminded of ABUS's next earnings announcement.

What was ABUS's revenue last quarter?

On Invalid Date, Arbutus Biopharma (NASDAQ: ABUS) reported Q4 2023 revenue of $2.15 million up 65.65% year over year. In the same quarter last year, Arbutus Biopharma's revenue was $6.25 million.

What was ABUS's revenue growth in the past year?

As of Q2 2024, Arbutus Biopharma's revenue has grown -53.51% year over year. This is 202.14 percentage points lower than the US Biotechnology industry revenue growth rate of 148.64%. Arbutus Biopharma's revenue in the past year totalled $18.14 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.